Renowned Immunologist and Urological Surgeon Dr. Marvin Hausman Featured in New Exousia Bio, Inc. Interview

Rhea-AI Summary

Exousia Bio (OTCPINK:LMMY) released an interview dated Dec 4, 2025 featuring strategic consultant Dr. Marvin Hausman, an immunologist and board‑certified urological surgeon with over 50 years of drug development experience.

Dr. Hausman described prior roles at major pharma organizations and said he helped obtain six NDAs. He expressed support for exosome‑based cancer therapies and highlighted interest in treating glioblastoma and advancing approaches for small cell lung cancer. The interview is available at the provided YouTube link.

News Market Reaction

+4.76%

1 alert

+4.76% News Effect

On the day this news was published, LMMY gained 4.76%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Experience: Over 50 years NDAs obtained: 6 NDAs Orphan exclusivity: 7 years +5 more

8 metrics

Experience Over 50 years Dr. Hausman drug development background

NDAs obtained 6 NDAs Major pharmaceutical companies supported by Dr. Hausman

Orphan exclusivity 7 years FDA Orphan Drug Designation for glioblastoma therapy

Current price $0.40 Pre‑news trading level on Dec 4, 2025

52-week high $16.00 Reported 52‑week high vs current price

52-week low $0.06 Reported 52‑week low vs current price

Acquisition shares 62,223,000 shares All‑stock acquisition of Exousia AI by LMMY

Unrestricted float 2,527,000 shares Post‑transaction float from Nov 17, 2025 disclosure

Market Reality Check

Price: $0.3859 Vol: Volume 2,851 is about in ...

low vol

$0.3859 Last Close

Volume Volume 2,851 is about in line with but below the 6,905 20-day average (relative volume 0.41). low

Technical Shares trade below the 200-day moving average at 2.91, indicating a longer-term downtrend pre‑news.

Peers on Argus

LMMY gained 3.9% while most listed consumer‑defensive education peers were flat;...

LMMY gained 3.9% while most listed consumer‑defensive education peers were flat; only ASPU rose meaningfully at 14.29%, suggesting a stock‑specific move rather than a broad sector shift.

Historical Context

4 past events · Latest: Dec 04 (Positive)

Pattern 4 events

Date	Event	Sentiment	Move	Catalyst
Dec 04	Executive interview	Positive	+4.8%	Interview highlighting expert advisor backing exosome-based oncology strategy.
Dec 02	Licensing agreement	Positive	+3.6%	Exclusive worldwide license for exosome cancer diagnostic and therapy platforms.
Dec 02	Acquisition & ODD	Positive	+3.6%	All-stock buy of Exousia AI plus exosome tech licenses and FDA ODD.
Nov 17	Control transaction	Positive	+105.4%	Exousia Pro becomes controlling shareholder; outlines exosome-focused growth plan.

Pattern Detected

Recent company news, including acquisitions and licensing deals, has consistently coincided with positive price reactions, including one triple‑digit move after the November 17, 2025 realignment.

Recent Company History

This announcement continues a series of oncology‑focused developments for LMMY. In mid‑November 2025, Exousia Pro transferred Exousia AI into LAMY, creating a controlling shareholder structure and outlining low float metrics. Shortly after, LMMY completed an all‑stock acquisition of Exousia AI and highlighted FDA Orphan Drug Designation for its glioblastoma therapy. On Dec 2, 2025, the company secured exclusive exosome technology licenses from the University of Central Florida. Today’s interview with Dr. Hausman reinforces this exosome‑based cancer strategy by emphasizing deep drug‑development experience and focus on indications like glioblastoma and small cell lung cancer.

Market Pulse Summary

This announcement highlights Exousia Bio’s strategy of reinforcing its exosome‑based cancer platform...

Analysis

This announcement highlights Exousia Bio’s strategy of reinforcing its exosome‑based cancer platform with seasoned leadership. Dr. Hausman brings over 50 years of drug development experience and a role in six NDAs, supporting the company’s focus on hard‑to‑treat cancers like glioblastoma and small cell lung cancer. In context with recent acquisitions, licenses, and FDA Orphan Drug Designation, the interview underscores a pivot from legacy operations toward oncology, while earlier SEC filings still flag going‑concern and funding risks.

Key Terms

exosome-based cancer therapy, exosomes, extracellular vesicles, mRNA, +2 more

6 terms

exosome-based cancer therapy medical

"operating as a leading U.S. biotechnology company focused on exosome-based cancer therapy"

A therapy that uses exosomes—tiny, naturally produced parcels released by cells—as delivery vehicles to carry drugs, genetic material or signals directly to cancer cells; think of them as microscopic courier packages that can home in on tumors. Investors should care because this approach promises more precise treatment with potentially fewer side effects, but success depends on proving safety, consistent manufacturing at scale and regulatory approval, which affect commercial potential and risk.

exosomes medical

"Exosomes represent the future of healthcare. As the smallest extracellular vesicles"

Exosomes are tiny particles released by cells that carry proteins, genetic material, and other molecules from one cell to another. They act like biological messengers, helping cells communicate and coordinate their activities. For investors, understanding exosomes is important because they are being explored as potential tools for disease diagnosis and treatment, which could influence healthcare markets and innovation.

extracellular vesicles medical

"As the smallest extracellular vesicles, they serve as the body’s communication system"

Extracellular vesicles are tiny, cell-made particles—think microscopic bubbles—that carry proteins, genetic material and signals between cells. Investors care because these vesicles can be used as disease markers, drug-delivery vehicles, or therapeutic products; that creates opportunities and risks around clinical validation, manufacturing scale-up, intellectual property and regulatory approval that can materially affect the value of biotech and diagnostics companies.

mRNA medical

"carrying mRNA, proteins, and amino acids between cells, whether cancerous or healthy"

mRNA, short for messenger ribonucleic acid, is a biological molecule that carries instructions from a cell’s genetic blueprint to make specific proteins — like a recipe or software code that tells a kitchen or computer what to produce. Investors care because mRNA is used as a flexible drug and vaccine platform that can be developed and scaled faster than many traditional medicines; its commercial prospects, manufacturing needs, regulatory approval path, and patent position can strongly affect a company’s value.

glioblastoma medical

"advancing the use of exosomes in treating devastating cancers such as glioblastoma"

Glioblastoma is a fast-growing and aggressive type of brain tumor that can affect a person's thinking, movement, or senses. Its seriousness and difficulty to treat can lead to significant health impacts, making it a concern for medical research and drug development. For investors, advances or setbacks in glioblastoma treatments can influence biotech companies and healthcare markets focused on cancer therapies.

small cell lung cancer medical

"and in pioneering approaches like those recently announced for small cell lung cancer"

A fast-growing form of lung cancer that tends to spread early to other organs, making it harder to treat than many slower-moving tumors. Investors care because its aggressive nature creates urgent demand for effective drugs, diagnostics and treatments; clinical trial results, regulatory decisions, or new therapies for this disease can quickly reshape a company’s revenue prospects much like a breakthrough product can transform a business in any industry.

AI-generated analysis. Not financial advice.

Drawing on over 50 years of drug development experience, Dr. Hausman strengthens the Company’s mission to combat cancer and other serious diseases.

ORLANDO, Fla., Dec. 04, 2025 (GLOBE NEWSWIRE) -- LAMY, to become Exousia Bio, Inc. (OTCPINK: LMMY) (the “Company” or “Exo Bio”), operating as a leading U.S. biotechnology company focused on exosome-based cancer therapy, announced the release of a new interview with strategic consultant Dr. Marvin Hausman, an esteemed Immunologist and Board-Certified Urological Surgeon. With more than five decades of experience in drug research and development, Dr. Hausman has contributed to groundbreaking work at leading pharmaceutical organizations including Bristol-Myers International, Mead-Johnson Pharmaceutical Co., E.R. Squibb, and Medco Research (now part of Pfizer). His insights bring unparalleled expertise to the Company’s strategic initiatives and underscore its commitment to advancing innovation in healthcare.

In the discussion, Hausman highlighted his career and where he hopes to take Exousia Bio, "I have been privileged to play a role in successfully obtaining six NDAs for major pharmaceutical companies. At Medco, one of the drugs we developed was Wellbutrin, which has become one of the world’s leading antidepressants. What I truly value is the ability to bridge medicine and business, and my goal is to leave a lasting legacy in the fight against cancer, the field where my work first began.”

In terms of where he thinks Exo Bio can thrive, he stated, "Exosomes represent the future of healthcare. As the smallest extracellular vesicles, they serve as the body’s communication system - carrying mRNA, proteins, and amino acids between cells, whether cancerous or healthy. I am fascinated by their potential and aspire to leave a legacy in healthcare with Exousia Bio by advancing the use of exosomes in treating devastating cancers such as glioblastoma, and in pioneering approaches like those recently announced for small cell lung cancer."

For the full interview, please visit: https://youtu.be/XnfMHqBwBoI

About LAMY (to become) Exousia Bio, Inc.

Exousia Bio, Inc., a leader in exosome-based biotechnology, develops and manufactures mammalian and plant-derived exosomes using proprietary technologies for nucleic acid loading and targeted delivery to tissues and cells. The platform enables the custom production of exosomes with enhanced genetic functionality, capable of selectively targeting specific cells to address diseases with significant unmet medical needs. These engineered exosomes have demonstrated the potential to target cancer stem cells, the primary drivers of recurrence and metastasis in various cancers, including glioblastoma and pancreatic cancer. The same platform technology also holds promise for treating a broad spectrum of viral infections.

SAFE HARBOR

Forward-looking statements in this release are made under the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. LAMY's forward-looking statements do not guarantee future performance. This news release includes forward-looking statements concerning the parties' future level of business. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of LAMY, and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects, as well as changes in products and competition.

CONTACT:
Exousia Bio, Inc.
www.exousiabio.com
X: @ExousiaBio
Investor Relations
ir@exousiabio.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/8189ad48-2a0e-422a-b471-1920f6d71b76

FAQ

Who is Dr. Marvin Hausman and what is his role with Exousia Bio (LMMY)?

Dr. Marvin Hausman is an immunologist and board‑certified urological surgeon serving as a strategic consultant to Exousia Bio (LMMY).

When was the Exousia Bio (LMMY) interview with Dr. Marvin Hausman published?

The interview was released on December 4, 2025.

What experience did Dr. Hausman cite in the LMMY interview?

He cited over 50 years in drug development and involvement in obtaining six NDAs at major pharmaceutical organizations.

Which cancer targets did Dr. Hausman highlight for Exousia Bio (LMMY)?

He highlighted advancing exosome‑based approaches for glioblastoma and small cell lung cancer.

What technology did Dr. Hausman emphasize in the LMMY interview?

He emphasized the potential of exosomes as cellular communication vehicles carrying mRNA, proteins, and amino acids for therapeutic use.

Where can investors watch the Exousia Bio (LMMY) interview with Dr. Marvin Hausman?

The full interview is available via the company's published YouTube link: https://youtu.be/XnfMHqBwBoI.